Literature DB >> 28394366

Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma.

J El Cheikh1, R Massoud1, I Abudalle1, B Haffar1, R Mahfouz2, M A Kharfan-Dabaja3, T Jisr4, A Mougharbel4, A Ibrahim4, A Bazarbachi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28394366     DOI： 10.1038/bmt.2017.69

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Authors:  Norbert Schmitz; Beate Pfistner; Michael Sextro; Markus Sieber; Angelo M Carella; Matthias Haenel; Friederike Boissevain; Reinhart Zschaber; Peter Müller; Hartmut Kirchner; Andreas Lohri; Susanne Decker; Bettina Koch; Dirk Hasenclever; Anthony H Goldstone; Volker Diehl
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

Authors:  Philippe Armand; Margaret A Shipp; Vincent Ribrag; Jean-Marie Michot; Pier Luigi Zinzani; John Kuruvilla; Ellen S Snyder; Alejandro D Ricart; Arun Balakumaran; Shelonitda Rose; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

3.  Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.

Authors:  Manuel Afable; Paolo F Caimi; Chitra Hosing; Marcos de Lima; Issa Khouri; Basem M William; Yago Nieto; Brenda W Cooper; Paolo Anderlini; Stanton L Gerson; Hillard M Lazarus; Richard Champlin; Uday Popat
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-30       Impact factor: 5.742

4.  Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.

Authors:  Pier Luigi Zinzani; Umberto Vitolo; Simonetta Viviani; Paolo Corradini; Giovanna Motta; Monica Tani; Nicola Cascavilla; Stefan Hohaus; Francesco Merli; Lisa Argnani; Alessandro Broccoli
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-03-05

5.  Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi.

Authors:  Antonella Anastasia; Carmelo Carlo-Stella; Paolo Corradini; Flavia Salvi; Chiara Rusconi; Alessandro Pulsoni; Stefan Hohaus; Patrizia Pregno; Simonetta Viviani; Ercole Brusamolino; Stefano Luminari; Laura Giordano; Armando Santoro
Journal:  Br J Haematol       Date:  2014-03-07       Impact factor: 6.998

6.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

7.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

8.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

9.  Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective.

Authors:  Jose Caetano Villasboas; Stephen M Ansell; Thomas E Witzig
Journal:  Oncotarget       Date:  2016-03-15

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more
  17 in total

Review 1.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

Review 2.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Authors:  Awais Ijaz; Ali Younas Khan; Saad Ullah Malik; Warda Faridi; Muhammad Asad Fraz; Muhammad Usman; Muhammad Junaid Tariq; Seren Durer; Ceren Durer; Atlantis Russ; Nadia Nunes Cavalcante Parr; Zeeshan Baig; Fnu Sagar; Zeeshan Ali; Ali McBride; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-06       Impact factor: 5.742

Review 3.  Clinical Development of PD-1 Blockade in Hematologic Malignancies.

Authors:  Matthew J Pianko; Aaron D Goldberg; Alexander M Lesokhin
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

Review 4.  Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.

Authors:  Arnab Ghosh; Ioannis Politikos; Miguel-Angel Perales
Journal:  Curr Opin Oncol       Date:  2017-11       Impact factor: 3.645

Review 5.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Blood Adv       Date:  2017-11-28

Review 7.  Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.

Authors:  Xiao-Yin Zhang; Graham P Collins
Journal:  Curr Oncol Rep       Date:  2022-06-13       Impact factor: 5.075

8.  Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.

Authors:  Ayumu Ito; Sung-Won Kim; Ken-Ichi Matsuoka; Toshiro Kawakita; Takashi Tanaka; Yoshihiro Inamoto; Tomomi Toubai; Shin-Ichiro Fujiwara; Masafumi Fukaya; Tadakazu Kondo; Junichi Sugita; Miho Nara; Yuna Katsuoka; Yosuke Imai; Hideyuki Nakazawa; Ichiro Kawashima; Rika Sakai; Arata Ishii; Makoto Onizuka; Tomonari Takemura; Seitaro Terakura; Hiroatsu Iida; Mika Nakamae; Kohei Higuchi; Shinobu Tamura; Satoshi Yoshioka; Kazuto Togitani; Noriaki Kawano; Ritsuro Suzuki; Junji Suzumiya; Koji Izutsu; Takanori Teshima; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2020-08-03       Impact factor: 2.490

Review 9.  Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.

Authors:  Matthew J Pianko; Alison J Moskowitz; Alexander M Lesokhin
Journal:  Clin Cancer Res       Date:  2017-09-12       Impact factor: 12.531

Review 10.  Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies.

Authors:  Razan Mohty; Rémy Dulery; Abdul Hamid Bazarbachi; Malvi Savani; Rama Al Hamed; Ali Bazarbachi; Mohamad Mohty
Journal:  Blood Cancer J       Date:  2021-07-09       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.